Arritmias provocadas por ondansetrón: Presentación de un caso
Resumen
Referencias
Morón Rodríguez FJ, Levi Rodríguez M. Farmacología General. La Habana: Ciencias Médicas; 2002.
Flórez J, Armijo JA, Mediavilla A. Farmacología humana. 6ª ed. Barcelona: Elsevier España; 2014.
Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
Brião FF, Horta ML, Horta BL, de Barros GA, Behrensdorf AP, Severo I, et al. Comparison of droperidol and ondansetron prophylactic effect on subarachnoid morphine-induced pruritus. Braz J Anesthesiol. 2015 Jul-Aug;65(4):244-8.
Ministerio de Salud Pública. Formulario Nacional de Medicamentos. La Habana: Editorial Ciencias Médicas; 2014.
Tricco AC, Soobiah C, Antony J, Hemmelgarn B, Moher D, Hutton B, et al. Safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery and chemotherapy: protocol for a systematic review and network meta-analysis. Syst Rev [Internet]. 2013 [citado 31 Mar 2019];2:46. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702491/pdf/2046-4053-2-46.pdf
McKechnie K, Froese A. Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome. Can J Anesth. 2010;57(5):453-7.
Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol. 2005;28(2):201-4.
Freedman SB, Hall M, Shah SS, Kharbanda AB, Aronson PL, Florin TA, et al. Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis. JAMA Pediatr. 2014;168(4):321-9.
Brenner SM, Boucher J. Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron. Pediatr Emerg Care. 2016;32(11):779-84.
Faria C, Li X, Nagl N, McBride A. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014;7(1):50-8.
Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22(2):469-77.
Enlaces refback
- No hay ningún enlace refback.
![Licencia de Creative Commons](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.